Citations

Clear

1422 citation(s) found for "Sn, Huang".

Hematopoietic Stem Cells Derived From Adult Donors Are Not a Source of Pancreatic β-Cells in Adult Nondiabetic Humans
Butler, Alexandra E. , Huang, Andrew T. , Rao, P. Nagesh, Bhushan, Anil , Rizza, Robert A., Butler, Peter C. , Hogan, William J.

Mayo Clinic

Diabetes | June 27, 2007 | Volume: 56 | Issue: 7 | Pages: 1810-1816

10.2337/db06-1385 | PMID 17456852 Get It

OBJECTIVE—Type 1 and type 2 diabetes are characterized by an ∼98 and ∼65% loss of pancreatic β-cells, respectively. Efforts to reverse either form of diabetes increasingly focus on the possibility of promoting β-cell replacement and/or regeneration. Islet transplantation has been explored, but it does not provide long-term insulin independence. One possible source of β-cell regeneration is hematopoietic stem cells. In mice, there are conflicting data as to whether hematopoietic stem cells contribute to pancreatic β-cells. We sought to establish whether hematopoietic stem cells (derived from adult donors) transdifferentiate into pancreatic β-cells in adult humans. RESEARCH DESIGN AND METHODS—We addressed this in 31 human pancreata obtained at autopsy from hematopoietic stem cell transplant recipients who had received their transplant from a donor of the opposite sex. RESULTS—Whereas some donor-derived cells were observed in the nonendocrine pancreata, no pancreatic β-cells were identified that were derived from donor hematopoietic stem cells, including two cases with type 2 diabetes. CONCLUSIONS—We conclude that hematopoietic stem cells derived from adult donors contribute minimally to pancreatic β-cells in nondiabetic adult humans. These data do not rule out the possibility that hematopoietic stem cells contribute to pancreatic β-cells in childhood or in individuals with type 1 diabetes.
Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib
Mulligan, George , Mitsiades, Constantine S. , Bryant, Barbara M. , Roels, Steven , Koenig, Erik , Fergus, Andrew, Huang, Yongsheng , Richardson, Paul G. , Trepicchio, William L. , Broyl, Annemiek, Sonneveld, Pieter , Shaughnessy, John D. , Bergsagel, P. Leif , Schenkein, David P., Esseltine, Dixie‐Lee, Boral, Anthony, Zhan, Fenghuang , Zhan, Fenghuang , Chng, Wee Joo , Richardson, Paul Gerard Guy , Anderson, Kenneth C. , Bergsagel, P. Leif , Zhan, Fenghuang , Mulligan, George

Mayo Clinic

Blood | December 21, 2006 | Volume: 109 | Issue: 8 | Pages: 3177-3188

10.1182/blood-2006-09-044974 | PMID 17185464 Get It

Abstract The aims of this study were to assess the feasibility of prospective pharmacogenomics research in multicenter international clinical trials of bortezomib in multiple myeloma and to develop predictive classifiers of response and survival with bortezomib. Patients with relapsed myeloma enrolled in phase 2 and phase 3 clinical trials of bortezomib and consented to genomic analyses of pretreatment tumor samples. Bone marrow aspirates were subject to a negative-selection procedure to enrich for tumor cells, and these samples were used for gene expression profiling using DNA microarrays. Data quality and correlations with trial outcomes were assessed by multiple groups. Gene expression in this dataset was consistent with data published from a single-center study of newly diagnosed multiple myeloma. Response and survival classifiers were developed and shown to be significantly associated with outcome via testing on independent data. The survival classifier improved on the risk stratification provided by the International Staging System. Predictive models and biologic correlates of response show some specificity for bortezomib rather than dexamethasone. Informative gene expression data and genomic classifiers that predict clinical outcome can be derived from prospective clinical trials of new anticancer agents.
Depletion of Zebrafish Titin Reduces Cardiac Contractility by Disrupting the Assembly of Z-Discs and A-Bands
Seeley, Michael, Huang, Wei , Chen, Zhenyue , Wolff, William Oscar, Lin, Xueying , Xu, Xiaolei

Mayo Clinic

Circulation Research | December 15, 2006 | Volume: 100 | Issue: 2 | Pages: 238-245

10.1161/01.res.0000255758.69821.b5 | PMID 17170364 Get It

The genetic study of titin has been notoriously difficult because of its size and complicated alternative splicing routes. Here, we have used zebrafish as an animal model to investigate the functions of individual titin isoforms. We identified 2 titin orthologs in zebrafish, ttna and ttnb , and annotated the full-length genomic sequences for both genes. We found that ttna , but not ttnb , is required for sarcomere assembly in the heart as well as the subsequent establishment of cardiac contractility. In fact, ttna is the earliest sarcomeric mRNA that is expressed in the heart, which makes it an early molecular marker for cardiomyocyte differentiation. Surprisingly, ttna is required for later steps of sarcomere assembly, including the assembly of Z-discs and A-bands, but not for early steps such as the assembly of Z-bodies and nonstriated myosin filaments. Reduction of individual titin isoforms in vivo using morpholino-modified antisense oligonucleotides indicated that (1) both N2B exon–containing and N2A exon–containing isoforms of ttna are required for sarcomere assembly in the heart; (2) N2A exon–containing isoforms of both ttna and ttnb are required for sarcomere assembly in the somites; and (3) the N2B exon–containing isoforms of ttnb are expressed later than other titin isoforms and are probably involved in modulating their expression; however, these isoforms of ttnb are not required for sarcomere assembly. Collectively, our results reveal distinct functions of different titin isoforms and suggest that various phenotypes in “titinopathies” may be attributable to the disruption of different titin isoforms.
CDK2-Dependent Phosphorylation of FOXO1 as an Apoptotic Response to DNA Damage
Regan, Kevin M., Tindall, Donald J., Huang, Haojie , Lou, Zhenkun , Chen, Junjie

Mayo Clinic

Science | October 12, 2006 | Volume: 314 | Issue: 5797 | Pages: 294-297

10.1126/science.1130512 | PMID 17038621 Get It

The function of cyclin-dependent kinase 2 (CDK2) is often abolished after DNA damage. The inhibition of CDK2 plays a central role in DNA damage–induced cell cycle arrest and DNA repair. However, whether CDK2 also influences the survival of cells under genotoxic stress is unknown. Forkhead box O (FOXO) transcription factors are emerging as key regulators of cell survival. CDK2 specifically phosphorylated FOXO1 at serine-249 (Ser 249 ) in vitro and in vivo. Phosphorylation of Ser 249 resulted in cytoplasmic localization and inhibition of FOXO1. This phosphorylation was abrogated upon DNA damage through the cell cycle checkpoint pathway that is dependent on the protein kinases Chk1 and Chk2. Moreover, silencing of FOXO1 by small interfering RNA diminished DNA damage–induced death in both p53-deficient and p53-proficient cells. This effect was reversed by restored expression of FOXO1 in a manner depending on phosphorylation of Ser 249 . Functional interaction between CDK2 and FOXO1 provides a mechanism that regulates apoptotic cell death after DNA strand breakage.
Modulation of Proliferating Renal Epithelial Cell Affinity for Calcium Oxalate Monohydrate Crystals
Farell, Gerard, Huang, Eric , Kim, S.Y., Horstkorte, R., Lieske, John C.

Mayo Clinic

Journal of Urology | April 6, 2006 | Volume: 175 | Issue: 5 | Pages: 1748-1749

10.1016/s0022-5347(06)00198-4 Get It

Foxo Factors: A Matter of Life and Death
Tindall, Donald J., Huang, Haojie

Mayo Clinic

Future Oncology | January 23, 2006 | Volume: 2 | Issue: 1 | Pages: 83-89

10.2217/14796694.2.1.83 | PMID 16556075 Get It

Rtt106p is a histone chaperone involved in heterochromatin-mediated silencing
Huang, Shengbing, Zhou, Hui , Katzmann, David J. , Hochstrasser, Mark , Atanasova, Elena, Zhang, Zhiguo

Mayo Clinic

Proceedings of the National Academy of Sciences | September 12, 2005 | Volume: 102 | Issue: 38 | Pages: 13410-13415

10.1073/pnas.0506176102 | PMID 16157874 Get It

Epigenetic inheritance of heterochromatin structure is an important cellular process whose mechanism remains elusive. In this article, we describe the identification of nine enhancers of the silencing defect of a Saccharomyces cerevisiae -PCNA mutant by screening a library of ≈4,700 viable yeast deletion mutants. Of the nine mutants identified, six ( hir1 , hir3 , sas2 , sas4 , sas5 , and sir1 ) were previously known to reduce silencing synergistically with a mutation in Cac1p, the large subunit of chromatin assembly factor 1 (CAF-1). The predicted gene products that are affected in three other mutants ( nam7 , msh2 , and rtt106 ) have not been implicated previously in silencing. Characterization of the rtt106 Δ allele revealed that it synergistically reduced heterochromatin silencing when combined with a mutation in Cac1p but not with a mutation in Asf1p (a histone H3 and H4 chaperone). Moreover, Rtt106p interacted with histones H3 and H4 both in vitro and in vivo , and it displayed a nucleosome assembly activity in vitro . Furthermore, Rtt106p interacts with CAF-1 physically through Cac1p. These biochemical and genetic data indicate that Rtt106p is a previously uncharacterized histone chaperone connecting S phase to epigenetic inheritance.
Quality of Life Outcomes From a Randomized Phase III Trial of Cisplatin With or Without Topotecan in Advanced Carcinoma of the Cervix: A Gynecologic Oncology Group Study
Monk, Bradley J. , Huang, Helen, Cella, David , Long, Harry J.

Mayo Clinic

Journal of Clinical Oncology | May 24, 2005 | Volume: 23 | Issue: 21 | Pages: 4617-4625

10.1200/jco.2005.10.522 | PMID 15911864 Get It

Purpose To prospectively assess the impact of treatment with cisplatin alone or in combination with topotecan (CT) on quality of life (QOL) in patients with advanced or recurrent cervical cancer, and to explore the prognostic value of baseline QOL scores. Patients and Methods Patients entered on Gynecologic Oncology Group (GOG) Protocol 179 were expected to complete QOL assessments at four time points using Functional Assessment of Cancer Therapy–General (FACT-G), Cervix subscale (Cx subscale), FACT/GOG–Neurotoxicity subscale (NTX subscale), Brief Pain Inventory (BPI), and UNISCALE (UNI). Adjusting for patient age, baseline scores, and effects of time, we longitudinally examined treatment effect on QOL during and after chemotherapy. Results Among patients randomly allocated to receive cisplatin (n = 146) or CT (n = 147), there were no statistically significant differences in QOL up to 9 months after randomization despite more hematologic toxicity in the combination arm. QOL assessments were completed at rates of 98%, 85%, 68%, and 59%, respectively, for the four time points, with similar rates and reasons for nonparticipation between regimens. Baseline FACT-G (P = .0016) and BPI (P = .0001) scores were significantly associated with patient age; older patients had better QOL and less pain. Baseline UNI was positively correlated with FACT-G (r = 0.66; P < .001) and Cx subscale (r = 0.29; P < .001), and negatively related to BPI (r = −0.41; P < .0001). Baseline FACT-Cx (FACT-G + Cx subscale) was associated with survival. Conclusion Despite increased toxicity, CT did not significantly reduce patient QOL when compared with cisplatin alone. Patient-reported QOL measures may be an important prognostic tool in advanced cervix cancer.
Localized glucose and water influx facilitates Cryptosporidium parvum cellular invasion by means of modulation of host-cell membrane protrusion
O’Hara, Steven P. , Huang, Bing , Splinter, Patrick L., Nelson, Jeremy B., Chen, Xian‐Ming , LaRusso, Nicholas F.

Mayo Clinic

Proceedings of the National Academy of Sciences | April 25, 2005 | Volume: 102 | Issue: 18 | Pages: 6338-6343

10.1073/pnas.0408563102 | PMID 15851691 Get It

Dynamic membrane protrusions such as lamellipodia and filopodia are driven by actin polymerization and often hijacked by intracellular microbes to enter host cells. The overall rate of membrane protrusion depends on the actin polymerization rate and the increase of localized cell volume. Although the signaling pathways involving actin polymerization are well characterized, the molecular mechanisms regulating local cell volume associated with membrane protrusion are unclear. Cryptosporidium parvum , an intracellular parasite, depends on host-cell membrane protrusion to accomplish cell entry and form the parasitophorous vacuole. Here, we report that C. parvum infection of cholangiocytes recruits host-cell SGLT1, a Na + /glucose cotransporter, and aquaporin 1 (AQP1), a water channel, to the attachment site. SGLT1-dependent glucose uptake occurs at the attachment site. Concordantly, the region of attachment displays localized water influx that is inhibited by either suppression of AQP1 by means of AQP1-small interfering RNA (siRNA) or inhibition of SGLT1 by a specific pharmacologic inhibitor, phlorizin. Inhibition of SGLT1 does not affect actin accumulation but decreases the membrane protrusion at the attachment site. Moreover, functional inhibition of host-cell AQP1 and SGLT1 hampers C. parvum invasion of cholangiocytes. Thus, glucose-driven, AQP-mediated localized water influx is involved in the membrane protrusion during C. parvum cellular invasion, phenomena that may also be relevant to the mechanisms of cell membrane protrusion in general.